CHARLOTTE LINDSEY: Open Payments
NPI 1326204405 · SAN ANGELO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$296 in 13 payments from 9 companies in 2025. Trend: 2023 $127 · 2024 $198 · 2025 $296
Food & beverage: $296
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $67 |
| Janssen Pharmaceuticals, Inc | 2 | $58 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 1 | $35 |
| ABBVIE INC. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
Products named: INGREZZA, INVEGA SUSTENNA, COBENFY, REXULTI, AUSTEDO XR, VRAYLAR, CAPLYTA, ARISTADA.
Industry payments across TX — which companies pay providers there.
